Bioventus Inc - Ordinary Shares - Class A
BVS
Get informed when a big investor buys or sells
+ FollowMarket Cap$937.63M
Close$
$25.28
76.1% upside
Current Fair Value
76.1% upsideUndervalued by 76.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $937.63 Million |
|---|---|
| Enterprise Value | $1.17 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.34 |
| Beta | 0.65 |
| Outstanding Shares | 67,869,148 |
Return
| Return on Equity | 23.86% |
|---|---|
| Return on Assets | 8.09% |
| Return on Invested Capital | 12.46% |
Valuation & Multiples
| P/E Ratio | 17.23 |
|---|---|
| PEG | 4.95 |
| Price to Sales | 1.8 |
| Price to Book Ratio | 3.59 |
| Enterprise Value to Revenue | 2.01 |
| Enterprise Value to EBIT | 18.05 |
| Enterprise Value to Net Income | 21 |
| Total Debt to Enterprise | 0.23 |
| Debt to Equity | 1.16 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$0.22
Average shareholder expectationRevenue Estimate
$155.44 M
Average shareholder expectationNext Earnings Call
Expected Date
November 3, 2026
EPS Estimate
$0.17
Average shareholder expectationRevenue Estimate
$149.51 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.2464▲ 0.88% |
|---|---|
| Total Calls | 211,000▲ 28.27% |
| Total Puts | 52,000▲ 32.99% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 80.61%▲ 4.74% |
|---|---|
| Total Invested | $513.74M▲ 10.15% |
| Investors Holding | 161▲ 2.00% |
ESG Score
No data
About Bioventus Inc
700 employeesBioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations For Active Healing from Bioven...